The cold chain infrastructure — a system of low-temperature storage and transport — remains a significant bottleneck in the global distribution of vaccines, enzymes, and diagnostic reagents. These protein-based products are inherently sensitive to temperature fluctuations, often degrading quickly if not maintained under strict refrigeration. The financial and environmental costs of this refrigeration are enormous, especially in developing countries where unreliable electricity supply causes frequent cold chain failures and high product wastage. The Oxford team’s MART drying technology addresses these challenges by enabling long-term stability of proteins without the need for freezing or refrigeration.

Published in the esteemed journal Engineering, the study led by Professor Zhanfeng Cui outlines the matrix-assisted drying process that mixes proteins with a sugar cocktail — specifically trehalose and dextran — and deposits the solution onto a soft cellulose fiber matrix. This matrix not only serves as a physical scaffold but also plays an instrumental role in forming microscopic capillary bridges during drying, which gently immobilize proteins within a stabilizing, sugar-derived glass. The drying process itself is conducted under mild conditions either by circulating dry air (MART-DA) or under vacuum (MART-V), completely eliminating the harsh freezing steps common in lyophilization that frequently damage delicate biomolecules.

Mechanistically, this technique achieves protein stabilization by harnessing the unique properties of the sugar matrix to maintain the native conformation of sensitive proteins during drying and subsequent storage. The trehalose and dextran sugars replace water molecules surrounding the proteins, forming hydrogen bonds that safeguard the tertiary and quaternary structure critical to biological activity. The chosen biocompatible cellulose fiber substrate facilitates a uniform distribution and thin film formation of the sugar-protein mixture, creating robust capillary bridges that encase each protein molecule within a protective vitrified state at room or slightly elevated temperatures (~30 °C).

The efficacy of MART drying was rigorously validated across multiple protein targets with varying structural complexities and thermal sensitivities. The enzyme lactate dehydrogenase (LDH), crucial in metabolic assays, retained an impressive >90% enzymatic activity after six months when stored at 25 °C, a performance equaling conventional frozen storage. Similarly, fibroblast growth factor 2 (FGF-2), which plays a pivotal role in stem cell proliferation and tissue regeneration, remained fully bioactive after a week of storage at 40 °C. Remarkably, when reconstituted, the MART-dried FGF-2 promoted stem cell growth on par with FGF-2 preserved at ultra-low temperatures (−80 °C). This bodes well for embedding growth factors into advanced wound dressings without cold-chain support.

Perhaps most striking is the successful thermostabilization of the COVID-19 RT-LAMP diagnostic reagent mix, which comprises enzymes reverse transcriptase and Bst 2.0 polymerase. After being MART-dried and stored at 40 °C for one week, the reagents retained sufficient sensitivity to detect viral RNA at clinically relevant levels. This demonstration underscores the broad applicability of MART drying to complex enzymatic cocktails essential for modern nucleic acid diagnostics, potentially enabling distributed testing in under-resourced regions without refrigeration.

MART drying outperforms traditional freeze-drying techniques on several fronts. The vacuum-assisted method can complete drying in approximately three hours, a substantial reduction from the 24 hours or more typical of lyophilization. By eliminating freezing and reducing processing complexity, MART drying consumes significantly less energy, translating into lower operational costs and reduced environmental impact. The use of a soft cellulose fiber matrix overcomes the brittleness and fragility associated with glass fiber matrices in previous prototypes, enhancing handling safety and enabling direct integration into biomedical devices.

Beyond supply chain simplification, the room-temperature stability enabled by MART drying could decentralize storage and deployment of sensitive biologics, extending the reach of advanced therapeutics and diagnostics to rural and low-income settings lacking infrastructure currently mandated by cold chain logistics. The technology’s scalability and compatibility with existing manufacturing workflows further enhance its translational potential, highlighting a new paradigm for sustainable biopharmaceutical preservation.

Scientifically, the development offers fresh insight into protein stabilization mechanisms within sugar glasses and advances the field of biomaterial engineering with its soft matrix design. This work supports a paradigm shift from dependence on cold storage toward ambient stabilization strategies, encouraging ongoing exploration into alternative excipients and matrix materials that preserve biological function while simplifying supply logistics.

Importantly, the research qualifies MART drying as a versatile platform that could be tailored for a wide array of sensitive biologics, from enzymes and growth factors to vaccines and nucleic acid diagnostics. The capability to maintain bioactivity at elevated temperatures addresses critical unmet needs in global health, particularly highlighted by the COVID-19 pandemic’s demand for distributed, temperature-resilient diagnostic tools.

As protein therapeutics continue to expand in complexity and demand, the ability to stabilize these molecules outside cold chains represents a transformative advance. This research spearheaded by the Oxford team not only promises to reduce wastage and cost but also to democratize access to life-saving medicines and diagnostics through robust storage solutions adaptable to challenging environments worldwide.

The full open-access report, titled “Thermostabilizing Functional Proteins with Matrix-Assisted Room-Temperature Drying,” authored by Yejiong Yu, Siqi Dai, Johnny Xiangyi Zhou, Wei E. Huang, and Zhanfeng Cui, was published in the journal Engineering on February 9, 2026. This pivotal work marks a major leap toward reimagining biopharmaceutical preservation for a sustainable and equitable healthcare future.

Subject of Research: Protein stabilization, biopharmaceutical preservation, ambient drying technology

Article Title: Thermostabilizing Functional Proteins with Matrix-Assisted Room-Temperature Drying

News Publication Date: February 9, 2026

Web References:
https://doi.org/10.1016/j.eng.2025.08.045
https://www.sciencedirect.com/journal/engineering

Image Credits: Yejiong Yu et al.

Keywords

Protein stabilization, MART drying, ambient temperature preservation, biopharmaceuticals, lyophilization alternative, sugar glass matrix, cellulose fiber matrix, enzymatic activity retention, COVID-19 diagnostics, cold chain disruption, thermostability, biocompatible excipients

The research spearheaded by Ko, Hu, Jeong, and their colleagues delves into advances within this critical field, emphasizing a patient-centered design philosophy that aims to cater to the actual needs of diverse populations. This focus not only acknowledges the technical requirements of vaccine formulation but also addresses the end-user experience, ensuring that vaccines are not only effective but also acceptable and manageable for patients and healthcare providers alike.

Thermostability is a paramount feature for vaccines, especially in regions where refrigeration may be inconsistent or unavailable. Traditional vaccines often rely on stringent cold chain logistics, which can complicate distribution and increase the risk of spoilage. Thus, innovations in chemical stability and formulation techniques are crucial for the future of vaccine commercialization. By using sophisticated formulation techniques, researchers have been able to manipulate the physical and chemical attributes of vaccine components, resulting in products that can withstand higher temperatures without losing their efficacy.

Among the groundbreaking technologies explored in this research are novel excipients and stabilizers that can enhance the durability of vaccine formulations. These materials often play a critical role in maintaining the structural integrity of the vaccine’s active ingredients and ensuring their bioavailability. Formulation scientists have employed a combination of surfactants, polymers, and cryoprotectants aimed at optimizing the thermal resilience of these therapeutic agents. The research highlights that selecting the right combination of these components can lead to significant improvements in thermal stability, ultimately impacting patient throughput during immunization campaigns.

Moreover, the patient-centered approach championed in this study recognizes that vaccine acceptance is tied not just to efficacy but also to factors like ease of administration, dosing schedules, and even the delivery route. This research advocates for the co-design of vaccines that take into consideration the perspectives and experiences of those who will ultimately receive them. Such an approach involves comprehensive feedback loops between researchers, healthcare providers, and communities, leading to formulations that are not only scientifically sound but also socially acceptable.

The article also suggests that technological advancements like lyophilization—the process of freeze-drying—can play a critical role in creating stable vaccine formulations. This technique essentially transforms liquid vaccines into dry powders that can be reconstituted prior to administration. The result is a product that not only boasts enhanced stability but can also allow for easier transportation and handling. As such, these lyophilized vaccines can expand the reach of immunization efforts in low-resource settings.

An integral aspect of vaccine formulation technology involves the use of adjuvants, which are substances that enhance the immune response. The research underscores the importance of carefully selecting adjuvants that complement the thermostable properties of the vaccine while ensuring that they do not induce undesirable side effects. The synergy between the active pharmaceutical ingredient and its adjuvant can be finely tuned to maximize both safety and efficacy, which is critical in developing vaccines that must meet rapid deployment conditions.

The role of antigen design within vaccine formulation is also highlighted as a vital component of research efforts. Advances in molecular biology and genetic engineering have paved the way for the creation of recombinant antigens that are more potent and easier to stabilize. These tailored antigens are designed with a focus on the immune evasion strategies of pathogens, promoting a robust immune response and ensuring longevity of immunity, particularly when combined with proper formulation techniques.

In addition to these technical considerations, the research also delves into the economic implications of deploying thermostable vaccines. By reducing the need for extensive cold chain logistics, these innovations can significantly lower the costs associated with vaccine distribution. This is particularly pertinent in resource-limited settings where healthcare budgets are often strained. The potential for greater access to vaccines could yield far-reaching benefits in public health, particularly in combating endemic diseases in developing countries.

Moreover, the integration of digital technology within vaccine development is becoming increasingly significant. The use of data analytics and modeling software can facilitate the optimization of formulation strategies and predict the performance of vaccines under various conditions. This innovative approach can provide real-time insights to researchers, allowing them to adapt and refine vaccine formulations rapidly in response to emerging data or field observations.

As we look toward the future of vaccine technology, the collective insights from this research serve as a clarion call for collaboration across disciplines. The intersection of pharmaceutical sciences, biotechnology, and patient-centered research opens new avenues for the creation of vaccines that are not only effective but also universally accessible. The approach encourages a more holistic view of vaccine development, where scientific rigor is complemented by a genuine consideration for the end-user experience, ultimately leading to more successful vaccination campaigns worldwide.

The implications of these findings extend beyond the immediate realm of vaccine production; they also resonate with the global mission to achieve equitable health for all. As the world grapples with the continual threat of infectious diseases, the importance of establishing robust and resilient vaccine development frameworks cannot be overstated. This research contributes a significant piece to that evolving puzzle, advocating for solutions that prioritize not just innovation, but also inclusivity and patient respect.

In conclusion, the advances described in this research by Ko and colleagues illuminate a path forward in the realm of vaccine formulation technologies. By blending scientific innovation with patient-centered designs and sustainable practices, the future of immunization appears brighter and more inclusive. Ensuring that everyone, regardless of their geographical or socio-economic status, has access to effective vaccines could one day be within our reach, paving the way for healthier populations globally.

Subject of Research: Thermostable vaccine platforms and patient-centered design in pharmaceutical formulation technologies.

Article Title: Advances in pharmaceutical formulation technologies for thermostable vaccine platforms considering patient-centered design.

Article References:

Ko, E., Hu, J., Jeong, Y. et al. Advances in pharmaceutical formulation technologies for thermostable vaccine platforms considering patient-centered design.
J. Pharm. Investig. (2025). https://doi.org/10.1007/s40005-025-00795-x

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s40005-025-00795-x

Keywords: Thermostable vaccines, pharmaceutical formulation, patient-centered design, vaccine technology, adjuvant development, lyophilization, antigen design, vaccine accessibility.